DrugBiological
Mosunetuzumab clinical trials
Also written BTCT4465A, RG 7828 and Lunsumio.
- studies test it
- 44
- open now
- 24
- in phase 3
- 5
- first study started
- 2015
Keep track of what changes. Save the mosunetuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Lunsumio
- 14
Studies by the year they started
44 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 10 |
| 2023 | 6 |
| 2024 | 11 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 33
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 30
Hoffmann-La Roche (11) · M.D. Anderson Cancer Center (4) · University of Washington (3) · National Cancer Institute (NCI) (3) · Washington University School of Medicine (2) · The Lymphoma Academic Research Organisation (2) · Genentech, Inc. (2) · City of Hope Medical Center (2)
Often tested with
Tested in the same studies.
Polatuzumab vedotin (9) · Lenalidomide (6) · Glofitamab (3) · Rituximab (2) · Obinutuzumab (2) · Atezolizumab (2) · Pirtobrutinib (2) · Tafasitamab (2)
Studies
Open first, then newest update. How each study uses mosunetuzumab is read from its arms, and is right about nine times in ten.
Testing it · 44
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaRecruitingPhase 3National Cancer Institute (NCI)NCT06337318Written as Mosunetuzumab
- A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisRecruitingPhase 2Hoffmann-La RocheNCT07598396Written as Mosunetuzumab
- Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone LymphomaRecruitingPhase 2Izidore Lossos, MDNCT06569680Written as Mosunetuzumab
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Mosunetuzumab
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05886036Written as Mosunetuzumab
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT05672251Written as Mosunetuzumab
- A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06563505Written as Mosunetuzumab
- Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)Not yet recruitingPhase 2University of UtahNCT07548450Written as Mosunetuzumab
- Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06453044Written as Mosunetuzumab
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingPhase 2M.D. Anderson Cancer CenterNCT05615636Written as Mosunetuzumab
- Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaRecruitingPhase 2University of WashingtonNCT06442475Written as Mosunetuzumab
- Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell LymphomaRecruitingPhase 2Medical College of WisconsinNCT06594939Written as Mosunetuzumab
- Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaRecruitingPhase 2Brown UniversityNCT04792502Written as Mosunetuzumab
- Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRDRecruitingPhase 2M.D. Anderson Cancer CenterNCT07566364Written as Mosunetuzumab
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT06015880Written as Mosunetuzumab
- Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell LymphomaRecruitingPhase 1/2OHSU Knight Cancer InstituteNCT06249191Written as Mosunetuzumab
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingPhase 3The Lymphoma Academic Research OrganisationNCT06006117Written as Mosunetuzumab (SC)
- Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular LymphomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07555470Written as Mosunetuzumab
- Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialRecruitingPhase 2University of WashingtonNCT06948786Written as Mosunetuzumab
- CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).RecruitingPhase 2Lazaros LekakisNCT05260957Written as Mosunetuzumab
See all 44 studies that test mosunetuzumab →
Given in every arm · 8 — mosunetuzumab is usual care beside what is tested
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruitingPhase 1/2Bristol-Myers SquibbNCT06090539Written as Mosunetuzumab
- Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07638722Written as Mosunetuzumab
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruitingPhase 1Hoffmann-La RocheNCT05091424Written as Mosunetuzumab
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Mosunetuzumab
- A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05389293Written as Mosunetuzumab
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Mosunetuzumab
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)Active, not recruitingPhase 1ADC Therapeutics S.A.NCT04970901Written as Mosunetuzumab
- Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell LymphomaActive, not recruitingPhase 1Washington University School of MedicineNCT05464329Written as Mosunetuzumab
Codes
What other systems call mosunetuzumab · ClinicalTrials.gg INT002162
- MeSH (NLM) C000731929mosunetuzumabOne source NLM
- UNII (FDA) LDJ89SS0YGMOSUNETUZUMABConfirmed FDA, NLM
- NCI Thesaurus C129691MosunetuzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731929 | mosunetuzumab | One source NLM |
| UNII (FDA) | LDJ89SS0YG | MOSUNETUZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C129691 | Mosunetuzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.